Abstract C39: GLUT1 and hemoglobin levels: Hypoxic markers of treatment response in patients with locally advanced cervical cancer.
Authors: Moreno-Acosta Pablo , Romero-Rojas Alfredo , Carrillo Schyrly , Gamboa Oscar , Acosta Jinneth , Balart-Serra Josep , Magne Nicolas 
Published: August 2014

Abstract
Background: The increased expression of GLUT1 and HKII CAIX in cervical cancer is associated with progression, metastasis, and poor survival rates. The aim of this study was to evaluate the predictive utility of GLUT1, CAIX, and HKII and hemoglobin levels versus tumor response to exclusive radiotherapy and concomitant chemoradiotherapy in patients with cervical carcinoma located. Methods: Sixty-six patients (FIGO IIB, IIIB) were included retrospectively for the period 2001-2007. Twenty-two of them received exclusive radiotherapy, and 44 received concurrent radiochemotherapy. The expression of GLUT1, CAIX, and HKII was studied by immunohistochemistry in paraffin-embedded biopsies taken before treatment. The expression levels of the proteins were correlated with clinical factors pathological, response to treatments (responders and non-responders), overall survival, and disease-free survival. Results: Of the 66 patients, 53 (80.3%) showed a complete response to treatment, of whom 16 received exclusive radiotherapy and 37 received concurrent radiochemotherapy. Protein expression levels of GLUT1, CAIX, and HKII were increased in cancer patients and as a particular feature of staining were observed that GLUT1 inmunostaining was frequently localized together to the blood vessels. Hemoglobin levels ≤ 11g/dl were statistically significant compared to the response to treatment (p=0.0127), with a trend of 4.3-fold risk of treatment failure in the group of nonresponders. We found that when expressed GLUT1, both the rate of overall survival and disease-free survival showed a trend risk of decrease of 1.1 times and 1.5 times respectively; when co-expressed GLUT1 and HKII was observed a trend risk of decrease of 1.6 times in the rate overall survival. Patients with hemoglobin levels ≤ 11g/dl had a risk 4.3-fold (p=0.02) decrease in both the overall survival rate as the rate of disease-free survival. Conclusion: The presence of anemic hypoxia (Hbg ≤ 11g/dl), expression of GLUT1, co-expression of GLUT1 and HKII, may influence the response to treatment, and therefore in overall and disease-free survival. The study and detection of these markers could contribute to infer the metabolic and hypoxic state of tumors, so that the therapeutic management may be optimized by considering such markers as predictive markers and/or as molecular targets.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C39.
Citation Format: Pablo Moreno-Acosta, Alfredo Romero-Rojas, Schyrly Carrillo, Oscar Gamboa, Jinneth Acosta, Josep Balart-Serra, Nicolas Magne. GLUT1 and hemoglobin levels: Hypoxic markers of treatment response in patients with locally advanced cervical cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C39.